Abstract
Bcl-2 or Bcl-XL confers resistance to chemotherapy in multiple myeloma (MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT-737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bossy-Wetzel E, Green DR . (1999). Apoptosis: checkpoint at the mitochondrial frontier. Mutat Res 434: 243–251.
Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351–365.
Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. (2005a). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8: 407–419.
Chauhan D, Hideshima T, Anderson KC . (2005b). Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45: 465–476.
Chou TC, Talalay P . (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
Cory S, Adams JM . (2005). Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8: 5–6.
Dalton WS . (2002). Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: NJ Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res. 8: 3658–3668. Clin Cancer Res 8: 3643–3645.
Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. (2001). Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3: 173–182.
Fulda S, Meyer E, Debatin KM . (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283–2294.
Gazitt Y, Fey V, Thomas C, Alvarez R . (1998). Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13: 397–405.
Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H et al. (1994). Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84: 3063–3070.
Jelinek DF, Witzig TE, Arendt BK . (1997). A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159: 487–496.
Kluck RM, Kashibatta S . (1997). A lively meeting of a deathly topic. Apoptosis 2: 337–342.
Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K et al. (2004). VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 104: 2886–2892.
Liston P, Fong WG, Korneluk RG . (2003). The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568–8580.
Liu Q, Gazitt Y . (2003). Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 101: 4105–4114.
Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. (2003). Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055–4062.
Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M . (1994). Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J Cell Biol 126: 827–837.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.
Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257–264.
Petros AM, Olejniczak ET, Fesik SW . (2004). Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83–94.
Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282–6293.
van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM . (2003). Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 17: 211–219.
Willie AH, Kerr JF, Currie AR . (1980). Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306.
Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. (2005). Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19: 1248–1252.
Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A . (1997). Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 97: 429–440.
Yang J, Liu X, Balla K, Kim CN, Ibardo NM, Cai J et al. (1997). Prevention of apoptosis by Bcl-2-release of cytochrome-c from the mitochondria blocked. Science 275: 1129–1136.
Acknowledgements
This investigation was supported by NIH grants RO-1 CA 50947, PO-1 CA 78373 and IP50CA10070, a Doris Duke Distinguished Clinical Research Scientist Award (KCA), The Myeloma Research Fund, and The Cure Myeloma Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chauhan, D., Velankar, M., Brahmandam, M. et al. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26, 2374–2380 (2007). https://doi.org/10.1038/sj.onc.1210028
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210028
Keywords
This article is cited by
-
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia
Current Treatment Options in Oncology (2021)
-
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells
Cell Death & Differentiation (2020)
-
Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia
Cell Death & Disease (2018)
-
Characterization of carfilzomib-resistant non-small cell lung cancer cell lines
Journal of Cancer Research and Clinical Oncology (2018)
-
Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer
International Journal of Clinical Oncology (2017)